NMN Regulatory Status Around the World
Regulatory status changes over time and can differ by product format, claims, dose, and route to market. This page reflects the record as understood on the last-reviewed date below, is not exhaustive of every jurisdiction worldwide, and should be independently verified before any commercial decision. It is educational information, not legal advice.
What this page is, and isn't
This is a comparative overview of jurisdictions where this hub could locate reasonably reliable primary regulatory information, not an exhaustive global legal survey. Every classification below is labeled either PRIMARY VERIFIED (this hub directly inspected an official government source establishing the status described) or INSUFFICIENT PRIMARY-SOURCE VERIFICATION (it could not). No category is assigned from secondary reporting alone. Full detail and sourcing for the United States, European Union, and Japan are on their own dedicated pages, linked below.
| Jurisdiction | Status | Primary basis | Key caveat |
|---|---|---|---|
| United States | PRIMARY VERIFIED (indirectly, via petitioner's own account) — Permitted / established route | FDA's own letters (Sept/Dec 2025) could not be directly retrieved despite exhausting available routes (regulations.gov, FDA.gov, Federal Register, archives). Directly verified instead: the petitioner NPA's own website states FDA determined NMN is not excluded from the dietary supplement definition.[1] | Not FDA's own text, directly inspected; not a drug-style approval; NDI adequacy is company-specific. See full page. |
| European Union | PRIMARY VERIFIED — Novel-food authorization required, not yet granted | European Commission's own records confirm an earlier NMN application was terminated (2022); a separate, later EffePharm application received a positive EFSA opinion (May 2026) but no Commission implementing act/Union List entry has been identified.[2][3] | A safety opinion is not a market authorization. See full page. |
| United Kingdom | PRIMARY VERIFIED — Novel-food authorization required, in progress | UK FSA's own regulated product applications database (RP-2116) shows EffePharm's application "In progress," at the "Risk assessment" stage of three.[4] | Earlier in the process than the equivalent EU application; a future EU decision does not automatically apply here. |
| Japan | INSUFFICIENT PRIMARY-SOURCE VERIFICATION (for NMN's specific listing) | Directly verified: the Foods with Function Claims system itself is self-certification, not government approval.[5] NMN's own MHLW non-drug-list entry and any specific product registrations could not be confirmed against primary Japanese government sources. | See full page for the full account of what was and wasn't verifiable. |
| Canada | PRIMARY VERIFIED — Permitted / established route | Health Canada's own Compendium of Monographs includes a Nicotinamide Mononucleotide monograph (dated August 28, 2024), classifying NMN as a Schedule 1 (isolate) Natural Health Product ingredient with defined approved uses (antioxidant, NAD+ precursor claims) and dose range (3–1,200 mg/day, not exceeding 600 mg per single dose).[6] | This is an established compendial pathway for Product Licence Applications, not a statement that every marketed product has completed licensing. |
| Australia | PRIMARY VERIFIED — Permitted / established route (single-sponsor exclusivity period) | TGA's own compositional guideline confirms NMN was added to the Permissible Ingredients Determination effective December 10, 2025 (oral route; reported maximum 500 mg/day; adults only, excluding pregnant/breastfeeding), with sponsor-specific exclusivity until December 10, 2027.[7] | The exclusivity period restricts which companies may currently rely on this specific pathway. |
| China | INSUFFICIENT PRIMARY-SOURCE VERIFICATION | Not verified against a Chinese primary regulatory source for this review. | No classification assigned. |
Reading the "status" column correctly
"PRIMARY VERIFIED" means this hub directly inspected an official government record establishing the described status — it does not mean risk-free, unregulated, or approved for any specific health claim, and in the U.S. case specifically it means this hub verified what the petitioner's own website states FDA determined, not FDA's own letter text directly (explained in full on the US page). "INSUFFICIENT PRIMARY-SOURCE VERIFICATION" means this hub is not making a claim either way, because it could not verify the status to its own standard after a genuine attempt — this is a statement about the limits of this review, not a statement about the underlying law.
What's common across jurisdictions
In every jurisdiction reviewed, regulatory status is distinct from, and does not depend on, the strength of the human clinical evidence covered elsewhere in this hub (see NMN Human Clinical Trials). Regulatory status also frequently depends on product format (food vs. supplement vs. therapeutic good), specific claims made on labeling and marketing, dose, and the exact route by which a product reaches consumers — a single "is NMN legal" answer for a whole country can be misleading once these variables are held constant one at a time.
Related reading
For full detail on the three jurisdictions with dedicated pages, see NMN Regulatory Status in the United States, NMN in Europe, and NMN in Japan. For how this hub verifies regulatory and scientific claims, see Research Methodology.
- This is a comparative overview, not an exhaustive global legal survey.
- Classifications are only assigned where a primary or near-primary source supports them.
- The US, Japan, and Australia each have a permitted route via different regulatory mechanisms.
- The EU and UK require novel-food premarket authorization not yet completed as of this review.
- Regulatory status is independent of the strength of the underlying human clinical evidence.
- Natural Products Association Amid Pressure From NPA, FDA Declares NMN Lawful In Dietary Supplements. npanational.org. 2025.Directly verified NPA's own statement; FDA's own letters could not be directly retrieved despite exhausting available routes. See US page for detail.
- European Commission Commission Implementing Decision of 31 March 2022 terminating the procedure for authorising the placing on the market within the Union of β-Nicotinamide mononucleotide as a novel food. European Commission official novel food register. 2022.C(2022) 1900 final. Directly verified via food.ec.europa.eu.
- EFSA Panel on Nutrition, Novel Foods and Food Allergens Safety of beta-nicotinamide mononucleotide (β-NMN) pursuant to Regulation (EU) 2015/2283. EFSA Journal. 2026. doi:10.2903/j.efsa.2026.10007.Directly verified via PMC13158811.
- UK Food Standards Agency Regulated Product Applications: β-Nicotinamide Mononucleotide (RP-2116). data.food.gov.uk. 2025-2026.Directly verified: status In progress, stage Risk assessment.
- Japan Consumer Affairs Agency Foods with Function Claims system overview. caa.go.jp. 2025-2026.Directly verified: self-certification system, not government approval. NMN's specific listing not independently confirmed.
- Health Canada Natural Health Product: Nicotinamide Mononucleotide (Compendial Monograph). Health Canada Compendium of Monographs / NHPID. 2024.Directly verified full monograph text: dated August 28, 2024, Schedule 1 isolate classification, dose range 3-1,200 mg/day.
- Australia Therapeutic Goods Administration Nicotinamide mononucleotide — compositional guideline and Permissible Ingredients Determination. tga.gov.au. 2025.Effective December 10, 2025; sponsor-specific exclusivity until December 10, 2027.